“…In recent years, a number of mechanisms involving inhibitor of apoptosis family proteins, BCL-2 family proteins, pro-survival protein kinase activation and cell-matrix interactions have been shown to regulate fibroblast susceptibility to apoptosis and accumulating studies demonstrate the feasibility of targeting fibroblast survival as a treatment strategy for fibrotic disease in the lung [ 1 , 4 , 21 , 24 , 36 , 37 ]. Additionally, several studies now indicate that regulation of Fas itself may contribute to fibroblast acquisition of an apoptosis-resistant phenotype, although our understanding of the underlying mechanisms continues to evolve [ 7 , 16 , 20 , 38 ]. In the current study, we have shown that pro-fibrotic soluble and mechanical stimuli suppress fibroblast expression of Fas through both transcriptional and post-transcriptional mechanisms, that decreased Fas correlates with resistance to apoptosis, and that enhanced apoptosis susceptibility in response to inflammatory cytokines is not diminished by TGF-β1 treatment.…”